Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Bidirectional ephrinB2‑EphB4 signaling regulates the osteogenic differentiation of canine periodontal ligament stem cells

Zhu S., Liu Z., Yuan C., Lin Y., Yang Y., Wang H.

Animal Study on Ligament Injury, published in Int J Mol Med (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Int J Mol Med (2020)
Reported sample size
—
Source database
Europe PMC
PMID
31985015
PMCID
PMC7015143
DOI
10.3892/ijmm.2020.4473
Citations
9

Abstract (original English)

The aim of the present study was to evaluate the effect of ephrinB2 gene‑transfected canine periodontal ligament stem cells (cPDLSCs) on the regulation of osteogenic differentiation. cPDLSCs were transfected with a transgenic null‑control green fluorescent protein (GFP) vector (termed Vector‑cPDLSCs) or with NFNB2 GFP‑Blasticidin (termed EfnB2‑cPDLSCs). Subsequently, the osteogenic differentiation of Vector‑cPDLSCs and EfnB2‑cPDLSCs was assessed by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR), alkaline phosphatase (ALP) assay and Alizarin Red S staining. The migratory abilities of cPDLSCs, Vector‑cPDLSCs and EfnB2‑cPDLSCs were also assessed. Following osteogenic induction of Vector‑cPDLSCs and EfnB2‑cPDLSCs, the protein expression levels of collagen I, Runt‑related transcription factor 2, osteocalcin, ephrin type‑B receptor 4 (EphB4), phospho‑EphB4, ephrinB2 and phospho‑ephrinB2 were analyzed by western blot assays. Following gene transfection, the RT‑qPCR and western blotting results revealed that the mRNA and protein expression levels of ephrinB2, respectively, were significantly increased in EfnB2‑cPDLSCs compared with that in Vector‑cPDLSCs (P<0.05). ALP and Alizarin Red S staining assays revealed increased ALP activity and mineralization nodules, respectively, in EfnB2‑cPDLSCs. Cell proliferation and migration assays revealed that EfnB2‑cPDLSCs ex

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Cells, CulturedStem CellsPeriodontal LigamentAnimalsDogsReceptor, EphB4Ephrin-B2Fluorescent Antibody TechniqueBlotting, WesternReverse Transcriptase Polymerase Chain Reaction

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research